 Paul Norman
Concepts (733)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 59 | 2025 | 98 | 10.280 |
Why?
| | Killer Cells, Natural | 55 | 2025 | 455 | 7.020 |
Why?
| | Haplotypes | 44 | 2025 | 494 | 4.340 |
Why?
| | Alleles | 48 | 2025 | 887 | 3.760 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 36 | 3.520 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 203 | 3.440 |
Why?
| | HLA Antigens | 21 | 2024 | 240 | 3.120 |
Why?
| | HLA-B Antigens | 21 | 2025 | 62 | 3.030 |
Why?
| | HLA-C Antigens | 19 | 2024 | 35 | 3.010 |
Why?
| | Polymorphism, Genetic | 32 | 2024 | 636 | 2.570 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 18 | 2.250 |
Why?
| | Genotype | 36 | 2025 | 1873 | 2.140 |
Why?
| | Immunogenetics | 5 | 2024 | 7 | 2.080 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 19 | 2.060 |
Why?
| | Evolution, Molecular | 18 | 2022 | 518 | 1.730 |
Why?
| | Genetic Variation | 19 | 2025 | 1003 | 1.350 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 541 | 1.340 |
Why?
| | Selection, Genetic | 12 | 2024 | 268 | 1.310 |
Why?
| | HLA-A Antigens | 11 | 2023 | 57 | 1.290 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.240 |
Why?
| | Employment | 4 | 2025 | 183 | 1.220 |
Why?
| | Humans | 201 | 2025 | 138651 | 1.200 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 215 | 1.130 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1310 | 1.110 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2025 | 95 | 1.070 |
Why?
| | Health Status Disparities | 6 | 2024 | 296 | 1.070 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 50 | 1.020 |
Why?
| | Retirement | 2 | 2025 | 32 | 1.000 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 76 | 0.990 |
Why?
| | Gene Frequency | 19 | 2025 | 504 | 0.970 |
Why?
| | Qualitative Research | 8 | 2025 | 1434 | 0.940 |
Why?
| | England | 12 | 2025 | 100 | 0.920 |
Why?
| | United Kingdom | 13 | 2025 | 321 | 0.900 |
Why?
| | Sequence Deletion | 1 | 2025 | 184 | 0.880 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 7 | 0.850 |
Why?
| | Medication Errors | 1 | 2024 | 96 | 0.850 |
Why?
| | Genome, Human | 6 | 2025 | 418 | 0.850 |
Why?
| | Residence Characteristics | 3 | 2021 | 366 | 0.830 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 192 | 0.790 |
Why?
| | Multimorbidity | 1 | 2023 | 48 | 0.790 |
Why?
| | Focus Groups | 3 | 2024 | 533 | 0.790 |
Why?
| | Ligands | 15 | 2023 | 665 | 0.780 |
Why?
| | Complement C4 | 2 | 2025 | 27 | 0.760 |
Why?
| | Herpesviridae | 1 | 2022 | 23 | 0.750 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.750 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1398 | 0.750 |
Why?
| | Minority Groups | 5 | 2024 | 274 | 0.730 |
Why?
| | Binge Drinking | 2 | 2021 | 45 | 0.720 |
Why?
| | Quality of Life | 15 | 2025 | 2954 | 0.720 |
Why?
| | Primates | 3 | 2019 | 138 | 0.720 |
Why?
| | Adaptation, Psychological | 7 | 2024 | 672 | 0.720 |
Why?
| | Health Promotion | 6 | 2024 | 745 | 0.710 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 148 | 0.710 |
Why?
| | Patient Safety | 1 | 2024 | 323 | 0.690 |
Why?
| | Communicable Diseases | 1 | 2023 | 161 | 0.690 |
Why?
| | DNA Copy Number Variations | 6 | 2025 | 178 | 0.680 |
Why?
| | Seizures | 4 | 2019 | 432 | 0.680 |
Why?
| | Genetic Predisposition to Disease | 14 | 2025 | 2368 | 0.670 |
Why?
| | Hearing Aids | 1 | 2021 | 76 | 0.670 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 912 | 0.660 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 231 | 0.650 |
Why?
| | Mortality | 2 | 2014 | 359 | 0.650 |
Why?
| | Censuses | 3 | 2017 | 34 | 0.640 |
Why?
| | Cross-Sectional Studies | 15 | 2024 | 5523 | 0.640 |
Why?
| | Genetics, Population | 10 | 2021 | 209 | 0.630 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 160 | 0.620 |
Why?
| | Somatoform Disorders | 2 | 2016 | 39 | 0.610 |
Why?
| | Peptides | 4 | 2022 | 984 | 0.590 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 365 | 0.590 |
Why?
| | Male | 68 | 2025 | 68216 | 0.590 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 661 | 0.590 |
Why?
| | Intensive Care Units | 1 | 2024 | 861 | 0.580 |
Why?
| | Poverty Areas | 2 | 2019 | 40 | 0.580 |
Why?
| | Point Mutation | 3 | 2017 | 239 | 0.570 |
Why?
| | Hearing Loss | 1 | 2021 | 219 | 0.570 |
Why?
| | Female | 75 | 2025 | 73913 | 0.570 |
Why?
| | Adult | 51 | 2025 | 38296 | 0.570 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.560 |
Why?
| | Heterozygote | 1 | 2019 | 305 | 0.560 |
Why?
| | Pan troglodytes | 9 | 2017 | 66 | 0.550 |
Why?
| | Language | 1 | 2020 | 302 | 0.550 |
Why?
| | Psoriasis | 3 | 2024 | 109 | 0.540 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 221 | 0.540 |
Why?
| | Genotyping Techniques | 4 | 2025 | 74 | 0.530 |
Why?
| | Health Status | 3 | 2025 | 820 | 0.530 |
Why?
| | Leukemia | 1 | 2019 | 241 | 0.520 |
Why?
| | Protein Binding | 10 | 2019 | 2236 | 0.510 |
Why?
| | Mucins | 1 | 2017 | 73 | 0.510 |
Why?
| | Rural Health Services | 3 | 2025 | 137 | 0.510 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 260 | 0.500 |
Why?
| | Middle Aged | 44 | 2025 | 33792 | 0.490 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 137 | 0.480 |
Why?
| | Burns | 3 | 2024 | 336 | 0.480 |
Why?
| | Population Dynamics | 2 | 2018 | 149 | 0.480 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 43 | 0.470 |
Why?
| | Weight Loss | 3 | 2019 | 785 | 0.470 |
Why?
| | Endovascular Procedures | 2 | 2022 | 347 | 0.470 |
Why?
| | Immunoglobulins | 4 | 2023 | 169 | 0.470 |
Why?
| | Family Relations | 1 | 2015 | 91 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2025 | 2143 | 0.450 |
Why?
| | Exons | 1 | 2016 | 355 | 0.450 |
Why?
| | Population | 1 | 2014 | 34 | 0.440 |
Why?
| | Wales | 5 | 2025 | 24 | 0.420 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.420 |
Why?
| | Self Concept | 3 | 2024 | 256 | 0.420 |
Why?
| | Immunity, Innate | 7 | 2024 | 828 | 0.420 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 418 | 0.420 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.410 |
Why?
| | Terminally Ill | 1 | 2014 | 37 | 0.410 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 827 | 0.410 |
Why?
| | Behavior Therapy | 4 | 2023 | 268 | 0.410 |
Why?
| | Malaria | 1 | 2013 | 64 | 0.400 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2103 | 0.390 |
Why?
| | Cell Line | 8 | 2019 | 2874 | 0.390 |
Why?
| | Longitudinal Studies | 9 | 2025 | 2838 | 0.390 |
Why?
| | Overweight | 1 | 2017 | 571 | 0.390 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 125 | 0.390 |
Why?
| | Stents | 2 | 2022 | 529 | 0.380 |
Why?
| | Young Adult | 20 | 2024 | 13322 | 0.380 |
Why?
| | Empathy | 2 | 2024 | 173 | 0.370 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1358 | 0.370 |
Why?
| | Aged | 26 | 2025 | 24182 | 0.360 |
Why?
| | Intention | 3 | 2021 | 174 | 0.360 |
Why?
| | Infant Mortality | 2 | 2024 | 115 | 0.350 |
Why?
| | Depression | 3 | 2023 | 1465 | 0.350 |
Why?
| | Cytomegalovirus | 3 | 2024 | 163 | 0.350 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2928 | 0.350 |
Why?
| | Life Style | 4 | 2017 | 484 | 0.340 |
Why?
| | T-Lymphocytes | 6 | 2024 | 1983 | 0.340 |
Why?
| | Emergency Medicine | 2 | 2024 | 237 | 0.340 |
Why?
| | Universities | 3 | 2021 | 440 | 0.330 |
Why?
| | Behcet Syndrome | 2 | 2021 | 18 | 0.330 |
Why?
| | Alcoholism | 1 | 2017 | 820 | 0.320 |
Why?
| | Health Behavior | 6 | 2025 | 776 | 0.320 |
Why?
| | Biological Evolution | 5 | 2019 | 486 | 0.320 |
Why?
| | Epitopes | 8 | 2019 | 476 | 0.320 |
Why?
| | Patient Compliance | 3 | 2025 | 599 | 0.320 |
Why?
| | Motor Neuron Disease | 2 | 2019 | 20 | 0.310 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2162 | 0.310 |
Why?
| | Australia | 4 | 2024 | 303 | 0.310 |
Why?
| | Body Image | 3 | 2024 | 99 | 0.310 |
Why?
| | Malnutrition | 2 | 2021 | 83 | 0.300 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 195 | 0.300 |
Why?
| | Recombination, Genetic | 2 | 2010 | 207 | 0.300 |
Why?
| | Models, Molecular | 5 | 2019 | 1598 | 0.300 |
Why?
| | Meiosis | 1 | 2009 | 84 | 0.300 |
Why?
| | Antigens, CD | 5 | 2017 | 537 | 0.290 |
Why?
| | Urban Population | 1 | 2011 | 481 | 0.290 |
Why?
| | Rural Population | 2 | 2018 | 579 | 0.290 |
Why?
| | Adolescent | 19 | 2024 | 21528 | 0.280 |
Why?
| | Alcohol Drinking | 4 | 2021 | 819 | 0.280 |
Why?
| | Life Change Events | 2 | 2019 | 152 | 0.280 |
Why?
| | Students | 3 | 2021 | 625 | 0.280 |
Why?
| | Energy Intake | 3 | 2025 | 506 | 0.270 |
Why?
| | Phylogeny | 12 | 2017 | 1007 | 0.270 |
Why?
| | Genomics | 6 | 2025 | 804 | 0.270 |
Why?
| | Chronic Disease | 1 | 2014 | 1800 | 0.270 |
Why?
| | China | 3 | 2024 | 213 | 0.270 |
Why?
| | Object Attachment | 2 | 2019 | 46 | 0.270 |
Why?
| | Oceania | 2 | 2024 | 4 | 0.270 |
Why?
| | Income | 2 | 2019 | 204 | 0.260 |
Why?
| | Signal Transduction | 4 | 2019 | 5091 | 0.260 |
Why?
| | Homozygote | 2 | 2025 | 203 | 0.260 |
Why?
| | Multigene Family | 3 | 2018 | 201 | 0.260 |
Why?
| | Immune System | 2 | 2019 | 181 | 0.260 |
Why?
| | Self-Management | 2 | 2019 | 181 | 0.250 |
Why?
| | Egypt | 2 | 2023 | 11 | 0.250 |
Why?
| | Infant, Newborn | 7 | 2024 | 6143 | 0.250 |
Why?
| | Centromere | 3 | 2025 | 59 | 0.250 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 4 | 0.250 |
Why?
| | Infant | 8 | 2024 | 9565 | 0.250 |
Why?
| | Caregivers | 4 | 2025 | 904 | 0.250 |
Why?
| | Animals | 29 | 2025 | 37309 | 0.250 |
Why?
| | Phenotype | 8 | 2024 | 3160 | 0.250 |
Why?
| | Virus Activation | 2 | 2024 | 85 | 0.240 |
Why?
| | Quality Improvement | 2 | 2024 | 1185 | 0.240 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 309 | 0.240 |
Why?
| | Codon | 2 | 2016 | 92 | 0.240 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 17 | 0.240 |
Why?
| | Software | 4 | 2025 | 667 | 0.240 |
Why?
| | Thymus Gland | 2 | 2024 | 314 | 0.240 |
Why?
| | Child | 11 | 2024 | 21883 | 0.240 |
Why?
| | Rural Health | 1 | 2025 | 83 | 0.230 |
Why?
| | Hominidae | 2 | 2019 | 84 | 0.230 |
Why?
| | Industry | 1 | 2025 | 68 | 0.220 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 37 | 0.220 |
Why?
| | Capacity Building | 1 | 2025 | 61 | 0.220 |
Why?
| | Occupations | 1 | 2024 | 50 | 0.220 |
Why?
| | Smoking | 5 | 2019 | 1607 | 0.220 |
Why?
| | Interpersonal Relations | 2 | 2019 | 409 | 0.220 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 17 | 0.220 |
Why?
| | Obesity | 1 | 2017 | 2994 | 0.220 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1069 | 0.220 |
Why?
| | Th17 Cells | 1 | 2025 | 108 | 0.210 |
Why?
| | Attitude to Health | 3 | 2019 | 457 | 0.210 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 140 | 0.210 |
Why?
| | Nutrition Therapy | 2 | 2025 | 35 | 0.210 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 95 | 0.210 |
Why?
| | Quinolines | 2 | 2024 | 151 | 0.210 |
Why?
| | Arabs | 2 | 2020 | 8 | 0.210 |
Why?
| | Pedigree | 1 | 2025 | 512 | 0.210 |
Why?
| | Cohort Studies | 8 | 2021 | 5729 | 0.210 |
Why?
| | Parkinson Disease | 2 | 2020 | 546 | 0.200 |
Why?
| | Alopecia Areata | 1 | 2023 | 13 | 0.200 |
Why?
| | Registries | 4 | 2021 | 2051 | 0.200 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 88 | 0.200 |
Why?
| | Immunity, Cellular | 1 | 2005 | 270 | 0.200 |
Why?
| | Waiting Lists | 1 | 2025 | 259 | 0.200 |
Why?
| | Gene Dosage | 3 | 2021 | 142 | 0.200 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2055 | 0.200 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 140 | 0.200 |
Why?
| | Iran | 2 | 2020 | 43 | 0.200 |
Why?
| | Unemployment | 1 | 2022 | 42 | 0.190 |
Why?
| | Incidence | 5 | 2020 | 2830 | 0.190 |
Why?
| | Computational Biology | 2 | 2025 | 650 | 0.190 |
Why?
| | Colon | 1 | 2025 | 287 | 0.190 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 183 | 0.190 |
Why?
| | Leukocytes | 1 | 2004 | 309 | 0.190 |
Why?
| | Social Stigma | 1 | 2024 | 143 | 0.190 |
Why?
| | Telomere | 4 | 2025 | 276 | 0.190 |
Why?
| | Health Services Research | 1 | 2025 | 405 | 0.190 |
Why?
| | Sequence Alignment | 3 | 2021 | 361 | 0.190 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1145 | 0.190 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.190 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5868 | 0.190 |
Why?
| | Patient Transfer | 1 | 2024 | 176 | 0.190 |
Why?
| | Colitis | 1 | 2025 | 267 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 28 | 0.180 |
Why?
| | Health | 1 | 2022 | 84 | 0.180 |
Why?
| | Age Factors | 5 | 2018 | 3274 | 0.180 |
Why?
| | Multilevel Analysis | 1 | 2021 | 34 | 0.180 |
Why?
| | Longevity | 1 | 2023 | 174 | 0.180 |
Why?
| | Eczema | 1 | 2022 | 68 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 334 | 0.180 |
Why?
| | New Zealand | 3 | 2018 | 54 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2025 | 294 | 0.180 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 12 | 0.180 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.180 |
Why?
| | Nutritionists | 1 | 2021 | 19 | 0.170 |
Why?
| | Malaysia | 1 | 2020 | 5 | 0.170 |
Why?
| | Professional Practice Location | 1 | 2021 | 29 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 151 | 0.170 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 111 | 0.170 |
Why?
| | HLA-D Antigens | 1 | 2021 | 33 | 0.170 |
Why?
| | Nutritional Support | 1 | 2021 | 35 | 0.170 |
Why?
| | Mindfulness | 1 | 2023 | 145 | 0.170 |
Why?
| | Plague | 1 | 2021 | 60 | 0.170 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 4 | 0.170 |
Why?
| | Exercise | 5 | 2019 | 2074 | 0.170 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 486 | 0.170 |
Why?
| | Motivation | 1 | 2025 | 588 | 0.170 |
Why?
| | Clinical Protocols | 2 | 2019 | 272 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 324 | 0.170 |
Why?
| | Hearing Tests | 1 | 2020 | 47 | 0.160 |
Why?
| | Child, Preschool | 7 | 2022 | 11130 | 0.160 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 621 | 0.160 |
Why?
| | Pregnancy | 6 | 2020 | 6836 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 153 | 0.160 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.160 |
Why?
| | Transportation | 1 | 2019 | 53 | 0.160 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.160 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.160 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 33 | 0.160 |
Why?
| | Diet, Diabetic | 1 | 2019 | 34 | 0.150 |
Why?
| | Hearing | 1 | 2020 | 118 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 855 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2025 | 460 | 0.150 |
Why?
| | B-Lymphocytes | 4 | 2017 | 856 | 0.150 |
Why?
| | Health Personnel | 3 | 2021 | 724 | 0.150 |
Why?
| | Base Sequence | 3 | 2016 | 2182 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 23 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 817 | 0.150 |
Why?
| | Bicycling | 1 | 2019 | 113 | 0.150 |
Why?
| | Phylogeography | 1 | 2019 | 59 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2019 | 55 | 0.150 |
Why?
| | Sex Factors | 4 | 2019 | 2058 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 644 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 393 | 0.150 |
Why?
| | Canada | 3 | 2024 | 412 | 0.140 |
Why?
| | Diet | 4 | 2019 | 1287 | 0.140 |
Why?
| | Parents | 2 | 2024 | 1420 | 0.140 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 48 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 53 | 0.140 |
Why?
| | Indians, South American | 2 | 2009 | 22 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 633 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 719 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 200 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2017 | 515 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 22 | 0.140 |
Why?
| | Eye Diseases | 1 | 2019 | 90 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2024 | 443 | 0.140 |
Why?
| | Middle East | 1 | 2017 | 17 | 0.140 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 170 | 0.140 |
Why?
| | Names | 1 | 2017 | 14 | 0.140 |
Why?
| | Flow Cytometry | 7 | 2018 | 1197 | 0.140 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 569 | 0.140 |
Why?
| | Genetic Testing | 4 | 2002 | 457 | 0.140 |
Why?
| | Binding Sites | 6 | 2015 | 1318 | 0.140 |
Why?
| | Walking | 2 | 2019 | 534 | 0.140 |
Why?
| | Epilepsy | 2 | 2019 | 337 | 0.140 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 88 | 0.130 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.130 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Osteosarcoma | 1 | 2018 | 73 | 0.130 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.130 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.130 |
Why?
| | Air Pollution | 1 | 2021 | 315 | 0.130 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 46 | 0.130 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 864 | 0.130 |
Why?
| | Transplantation, Homologous | 4 | 2024 | 415 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2602 | 0.130 |
Why?
| | Prevalence | 4 | 2019 | 2744 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 279 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 590 | 0.130 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 30 | 0.130 |
Why?
| | Risk Factors | 11 | 2025 | 10398 | 0.130 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 118 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 101 | 0.130 |
Why?
| | Angiotensin II | 1 | 2017 | 98 | 0.130 |
Why?
| | Virus Diseases | 1 | 2019 | 214 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 406 | 0.130 |
Why?
| | Anxiety | 3 | 2023 | 1066 | 0.130 |
Why?
| | Reference Standards | 1 | 2017 | 184 | 0.130 |
Why?
| | Gene Flow | 2 | 2015 | 84 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 100 | 0.130 |
Why?
| | Allied Health Personnel | 1 | 2016 | 51 | 0.130 |
Why?
| | Open Reading Frames | 1 | 2017 | 132 | 0.130 |
Why?
| | Polymerase Chain Reaction | 5 | 2017 | 1049 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 371 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 568 | 0.120 |
Why?
| | Feeding Behavior | 2 | 2019 | 684 | 0.120 |
Why?
| | Molecular Typing | 1 | 2016 | 22 | 0.120 |
Why?
| | Placentation | 2 | 2016 | 45 | 0.120 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 165 | 0.120 |
Why?
| | HIV-1 | 1 | 2022 | 888 | 0.120 |
Why?
| | Self Care | 2 | 2016 | 383 | 0.120 |
Why?
| | Dissociative Disorders | 1 | 2015 | 24 | 0.120 |
Why?
| | Curriculum | 1 | 2022 | 1005 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 944 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1494 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 78 | 0.120 |
Why?
| | Sf9 Cells | 1 | 2015 | 10 | 0.120 |
Why?
| | Crohn Disease | 1 | 2019 | 250 | 0.120 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7683 | 0.120 |
Why?
| | Spodoptera | 1 | 2015 | 40 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2024 | 3581 | 0.120 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 96 | 0.120 |
Why?
| | Human Migration | 1 | 2015 | 23 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2018 | 249 | 0.120 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 47 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1748 | 0.110 |
Why?
| | Insecta | 1 | 2015 | 70 | 0.110 |
Why?
| | Research Report | 1 | 2015 | 85 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
| | Social Class | 1 | 2017 | 279 | 0.110 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.110 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 224 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 372 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 129 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 91 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 530 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Time Factors | 8 | 2025 | 6877 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 64 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1449 | 0.110 |
Why?
| | Muscle Weakness | 1 | 2014 | 92 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 216 | 0.110 |
Why?
| | Attitude of Health Personnel | 2 | 2019 | 1157 | 0.110 |
Why?
| | Glucose | 1 | 2019 | 1032 | 0.100 |
Why?
| | Protein Folding | 1 | 2015 | 279 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2003 | 703 | 0.100 |
Why?
| | Mammals | 1 | 2015 | 286 | 0.100 |
Why?
| | Prospective Studies | 7 | 2024 | 7639 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 24 | 0.100 |
Why?
| | Tissue Donors | 4 | 2024 | 418 | 0.100 |
Why?
| | Counseling | 1 | 2016 | 390 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 237 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 2000 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 582 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.100 |
Why?
| | Genetics, Medical | 3 | 2019 | 25 | 0.100 |
Why?
| | Exome | 1 | 2014 | 235 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 1048 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 410 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2016 | 375 | 0.100 |
Why?
| | Stress, Psychological | 2 | 2016 | 1124 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3628 | 0.100 |
Why?
| | Metagenomics | 1 | 2014 | 177 | 0.100 |
Why?
| | Saliva | 1 | 2014 | 239 | 0.090 |
Why?
| | Hepatitis C | 1 | 2015 | 274 | 0.090 |
Why?
| | Graft Survival | 1 | 1995 | 527 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 34 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 273 | 0.090 |
Why?
| | Environment | 1 | 2013 | 339 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1108 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 400 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.090 |
Why?
| | Interviews as Topic | 2 | 2024 | 803 | 0.090 |
Why?
| | Graft Rejection | 1 | 1995 | 577 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2017 | 789 | 0.090 |
Why?
| | Internet | 1 | 2015 | 674 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 77 | 0.090 |
Why?
| | DNA Primers | 3 | 2018 | 509 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 621 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 1995 | 903 | 0.080 |
Why?
| | Europe | 2 | 2021 | 405 | 0.080 |
Why?
| | North America | 2 | 2021 | 311 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 741 | 0.080 |
Why?
| | Family | 1 | 2014 | 677 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 605 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1302 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2024 | 10938 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 77 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 487 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 252 | 0.080 |
Why?
| | Hospitalization | 2 | 2023 | 2219 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2017 | 999 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1810 | 0.070 |
Why?
| | Algorithms | 3 | 2024 | 1718 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2405 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 125 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 106 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2513 | 0.070 |
Why?
| | Africa | 3 | 2019 | 117 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 352 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 160 | 0.070 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2294 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1399 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 1015 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 374 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | HIV Infections | 1 | 2022 | 2944 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2531 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1368 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4333 | 0.060 |
Why?
| | Receptors, Fc | 1 | 2007 | 55 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 393 | 0.060 |
Why?
| | Genetic Counseling | 3 | 2002 | 78 | 0.060 |
Why?
| | Palliative Care | 1 | 2014 | 814 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 960 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 214 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 2 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 229 | 0.060 |
Why?
| | Norway | 1 | 2025 | 43 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 283 | 0.060 |
Why?
| | Mice | 5 | 2025 | 17848 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 9 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 30 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2861 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 18 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 390 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 138 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 53 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4175 | 0.060 |
Why?
| | Patient Satisfaction | 3 | 2024 | 679 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 3038 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3406 | 0.060 |
Why?
| | Models, Statistical | 2 | 2019 | 667 | 0.050 |
Why?
| | Logistic Models | 2 | 2021 | 2088 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 165 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5812 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 308 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 25 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 639 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 134 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 25 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 164 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 49 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 433 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 316 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 399 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 119 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 28 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 21 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2701 | 0.050 |
Why?
| | Risk Assessment | 4 | 2019 | 3459 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 45 | 0.050 |
Why?
| | Pakistan | 1 | 2002 | 76 | 0.050 |
Why?
| | Bangladesh | 1 | 2002 | 56 | 0.050 |
Why?
| | Pandemics | 2 | 2021 | 1637 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2002 | 177 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 535 | 0.050 |
Why?
| | India | 1 | 2002 | 197 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 25 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 56 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 38 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 325 | 0.040 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 123 | 0.040 |
Why?
| | Cytokines | 2 | 2025 | 2084 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 17 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 897 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 92 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1084 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 647 | 0.040 |
Why?
| | Geography | 1 | 2021 | 203 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 196 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 336 | 0.040 |
Why?
| | Twins | 1 | 2001 | 222 | 0.040 |
Why?
| | Risk | 2 | 2019 | 912 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 394 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 332 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 20 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 345 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 34 | 0.040 |
Why?
| | Newfoundland and Labrador | 1 | 2019 | 1 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 28 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 109 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 71 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 286 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 29 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 290 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 47 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 732 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 39 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 44 | 0.040 |
Why?
| | Interrupted Time Series Analysis | 1 | 2019 | 74 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 56 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 66 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 88 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 69 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3998 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 515 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1120 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 90 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2734 | 0.040 |
Why?
| | Cough | 1 | 2019 | 125 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 515 | 0.040 |
Why?
| | Posture | 1 | 2019 | 192 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 196 | 0.040 |
Why?
| | Particulate Matter | 1 | 2021 | 316 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2021 | 366 | 0.040 |
Why?
| | Narration | 1 | 2019 | 63 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 914 | 0.040 |
Why?
| | Biomarkers | 2 | 2021 | 4111 | 0.040 |
Why?
| | Parenting | 1 | 2022 | 315 | 0.040 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 37 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 170 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 417 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 148 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1102 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1162 | 0.030 |
Why?
| | Collagen Type III | 1 | 2017 | 18 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 19 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 6 | 0.030 |
Why?
| | Demography | 2 | 2013 | 296 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 7 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 164 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 398 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 380 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 563 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 19 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 52 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 99 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 79 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 22 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 167 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 252 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 613 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 396 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 92 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 994 | 0.030 |
Why?
| | Triage | 1 | 2019 | 231 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 133 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5160 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 176 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 109 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 250 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 848 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 171 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1876 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 398 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1437 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 232 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1454 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 98 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 75 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 327 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Americas | 1 | 2015 | 28 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 426 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 91 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 47 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 173 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 47 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 53 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 225 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 638 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 192 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1101 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 740 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 261 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 241 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 640 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 422 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 911 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 146 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 28 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 324 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 349 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 229 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 497 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 628 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 59 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 161 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 182 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 446 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 247 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 763 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 291 | 0.030 |
Why?
| | Inflammation | 1 | 2025 | 2857 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 28 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 304 | 0.030 |
Why?
| | United States | 2 | 2023 | 15018 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 300 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 87 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 373 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 261 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 271 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 205 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 189 | 0.030 |
Why?
| | Lung | 2 | 2019 | 4086 | 0.030 |
Why?
| | Asia | 2 | 2003 | 70 | 0.030 |
Why?
| | Cultural Competency | 1 | 2014 | 89 | 0.020 |
Why?
| | Ultrasonography | 1 | 2017 | 766 | 0.020 |
Why?
| | Ursidae | 1 | 2012 | 8 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 43 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 715 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1011 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 58 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 308 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 208 | 0.020 |
Why?
| | Genome | 1 | 2014 | 299 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 375 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 996 | 0.020 |
Why?
| | Feces | 1 | 2015 | 481 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 970 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 376 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 35 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 434 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 103 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3311 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1815 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 462 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 358 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 426 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 57 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1055 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 49 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 136 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 162 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 219 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 369 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 323 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4015 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 189 | 0.020 |
Why?
| | Culture | 1 | 2011 | 131 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1958 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2474 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 115 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 385 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 36 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1859 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 36 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 373 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 141 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 264 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 481 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 183 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 126 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1090 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 188 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 691 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 289 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 875 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 8 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 760 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 151 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 766 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 22 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 752 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 75 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 90 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 135 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 317 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 326 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1239 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 51 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1153 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2002 | 16 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 63 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 355 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1486 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 268 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 22 | 0.010 |
Why?
| | Utah | 1 | 2002 | 63 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 301 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 525 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 15860 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 41 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 176 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 63 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 867 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1497 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 246 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1320 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 433 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 454 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 10 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 797 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 31 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 14 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 9 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 24 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 40 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1707 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 204 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 435 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|